.Attributes Medication, Posted online: 16 September 2024 doi:10.1038/ s41591-024-03244-8In the observational SCRUM-Japan GOZILA research, after a median follow-up of 11 months, people along with metastatic gastrointestinal lumps that acquired biomarker-matched treatments based on circulating growth DNA profiling revealed a higher clinical perk than those obtaining unmatched therapy.